Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related MNKD
MannKind Triples Production Capacity for Afrezza
MannKind Continues To Decline
Related NVO
5 NYSE Healthcare Stocks With The Highest ROI
Conquering Hemophilia: Novo Nordisk Reports Encouraging Data From Phase III Trial Of NovoEight

Analysts at Bank of America downgraded MannKind (NASDAQ: MNKD) from “neutral” to “underperform.” The target price for MannKind has been lowered from $8 to $5. MannKind's shares closed at $6.30 yesterday.

Swedbank downgraded Novo Nordisk A/S (NYSE: NVO) from “strong buy” to “buy.” Novo Nordisk's shares closed at $162.53 yesterday.

SunTrust Robinson Humphrey downgraded Bank of the Ozarks (NASDAQ: OZRK) from “buy” to “neutral.” The target price for Bank of the Ozarks has been raised from $46 to $49. Bank of the Ozarks' shares closed at $46.01 yesterday.

Analysts at Credit Suisse downgraded M&T Bank (NYSE: MTB) from “outperform” to “neutral.” M&T Bank's shares closed at $115.91 yesterday.

Latest Ratings for MNKD

DateFirmActionFromTo
May 2015JP MorganDowngradesNeutralUnderweight
Mar 2015Goldman SachsDowngradesNeutralSell
Oct 2014Goldman SachsInitiates Coverage onNeutral

View More Analyst Ratings for MNKD
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (MNKD + MTB)

Get Benzinga's Newsletters